Stay up to date with the latest research and clinical updates on prostate cancer from the 2025 American Society of Clinical Oncology Annual Meeting.
The Two Onc Docs review QOL related to doublet ADT with darolutamide, niraparib with abiraterone for mCSPC, and more.
Dr. James showcases an MMAI model to identify benefit from 2nd-generation ARPIs in hr/nm PCa patients from STAMPEDE.
Adding niraparib to abiraterone and prednisone prolongs rPFS in patients with mCSPC harboring HRR gene alterations.
Drs. Ong and Roy detail a multinational real-world analysis of the IRONMAN registry on the significance of PSA>0.2.
Dr. Tagawa explains the rationale for EVOLUTION, a phase II analysis of Lu-PSMA-617 with ipilimumab and nivolumab in mCRPC.
Dr. Tagawa contextualizes a post hoc analysis on clonal hematopoiesis in those who received 177Lu-PSMA-617 or cabazitaxel.
Dr. Tagawa showcases the ProstACT Global trial, a phase III study of 177Lu-rosptamab in patients with mCRPC.
Dr. Tagawa breaks down the VIOLET study, a single-arm phase I/II first-in-human results of terbium-161Tb-PSMA-I&T.
Dr. Ozay discusses her study that compared the efficacy of cabazitaxel with lutetium Lu-177 in patients with mCRPC.
Drs. Privé and Tagawa discuss the BULLSEYE trial, an analysis of Lutetium-177-PSMA-617 in oligometastatic HSPC.
Louise Emmett, MD, discusses the ENZA-p trial which studied enzalutamide versus enzalutamide plus [177Lu] Lu-PSMA-617.
Researchers studied clonal hematopoiesis mutations in patients treated with 177Lu-PSMA-617 or cabazitaxel for prostate cancer
Five-year ARCHES follow-up evaluates the overall surival benefit of enzalutamide + ADT in patients with mHSPC.
Researchers suggest that darolutamide may delay deterioration of quality of life in patients with mHSPC.
Researchers evaluated SBRT plus short-term hormonal therapy in oligometastatic HSPC, examining the tolerability and efficacy.
A novel algorithm identifies patients with high-risk non-metastatic PCa who may benefit from second-generation ARPIs.
The addition of ipi/nivo to LuPSMA improved PSA-PFS over 12 months in patients with mCRPC.
Drs. Karine Tawagi and Samantha Armstrong share their thoughts on ARANOTE, Metacure, and more.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.